IDEAYA Biosciences, Inc. (IDYA): Price and Financial Metrics

IDEAYA Biosciences, Inc. (IDYA): $40.17

1.00 (-2.43%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

IDYA Price/Volume Stats

Current price $40.17 52-week high $47.74
Prev. close $41.17 52-week low $14.33
Day low $39.81 Volume 496,400
Day high $41.45 Avg. volume 857,693
50-day MA $44.10 Dividend yield N/A
200-day MA $33.23 Market Cap 3.00B

IDYA Stock Price Chart Interactive Chart >


IDEAYA Biosciences, Inc. (IDYA) Company Bio


IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.


IDYA Latest News Stream


Event/Time News Detail
Loading, please wait...

IDYA Latest Social Stream


Loading social stream, please wait...

View Full IDYA Social Stream

Latest IDYA News From Around the Web

Below are the latest news stories about IDEAYA BIOSCIENCES INC that investors may wish to consider to help them evaluate IDYA as an investment opportunity.

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on November 30, 2023, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 40,000 shares of the Company's common stock to a newly hired employee. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (

Yahoo | December 8, 2023

IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations event.

Yahoo | December 5, 2023

IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical study collaboration and supply agreement with Gilead Sciences, Inc. (Gilead) to evaluate the efficacy and safety of IDE397, its investigational, potential first-in-class, small molecule MAT2A inhibitor, in combination with Gilead's sacituzumab-govitecan-hziy ("Trodelvy"), a Trop-2 directed antibody-drug conjuga

Yahoo | December 4, 2023

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its Investor R&D Day. The webcast event will be hosted by IDEAYA on Monday, December 4, 2023 at 8:00 am to 9:30 am ET.

Yahoo | December 3, 2023

Can IDEAYA Biosciences, Inc. (IDYA) Climb 25.48% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for IDEAYA Biosciences, Inc. (IDYA) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 14, 2023

Read More 'IDYA' Stories Here

IDYA Price Returns

1-mo -9.34%
3-mo -2.10%
6-mo 58.84%
1-year 170.14%
3-year 118.55%
5-year N/A
YTD 12.90%
2023 95.82%
2022 -23.14%
2021 68.86%
2020 86.67%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!